BAN2802

About BioArctic

BioArctic is a research-driven biopharma company with a mission to develop transformative treatments for neurodegenerative diseases. Its strategic partnership with Eisai led to the landmark approval and commercialization of lecanemab for Alzheimer's, providing a foundational revenue stream. The company's core strategy is to leverage its proprietary BrainTransporter™ platform to build a diversified pipeline of next-generation biologics for Parkinson's and ALS, while continuing to advance its Alzheimer's franchise.

About bioarctic-ab

BioArctic AB is a research-intensive Swedish biopharma focused on translating novel insights into protein aggregation pathology into transformative treatments for neurodegenerative diseases. Its strategic triumph is the Eisai-partnered anti-amyloid beta protofibril antibody lecanemab (Leqembi®), which achieved FDA approval in 2023, validating the company's core scientific thesis. The company's strategy balances revenue from this landmark partnership with advancing a wholly-owned pipeline targeting alpha-synuclein in Parkinson's disease, leveraging its proprietary BrainTransporter® platform to enhance drug delivery to the brain. With a market cap nearing $28 billion, BioArctic stands as a premier European biotech success story.

Therapeutic Areas

Other Parkinson's Disease Drugs